The prognostic significance of phosphatidylinositol 3-kinase pathway activation in human gliomas

Journal of Clinical Oncology

Volumn 22, Issue 10, 2004, Pages 1926-1933

  Chakravarti, Arnab ^a   Zhai, Gary ^a   Suzuki, Yoshiyuki ^a   Sarkesh, Sormeh ^a   Black, Peter M ^a   Muzikansky, Alona ^a   Loeffler, Jay S ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CASPASE 3; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; PROTEIN P70; AKT1 PROTEIN, HUMAN; ONCOPROTEIN; PROTEIN SERINE THREONINE KINASE; S6 KINASE; TUMOR MARKER;

ADJUVANT THERAPY; APOPTOSIS; ARTICLE; CANCER GRADING; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; ENZYME ACTIVATION; FROZEN SECTION; GLIOBLASTOMA; GLIOMA; HISTOLOGY; HUMAN; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; RADIOSENSITIVITY; SURVIVAL; TREATMENT OUTCOME; CANCER STAGING; EVALUATION; GENE EXPRESSION REGULATION; METABOLISM; MORTALITY; PATHOLOGY; PREDICTION AND FORECASTING; PROSPECTIVE STUDY; UNITED STATES; WESTERN BLOTTING;

1-PHOSPHATIDYLINOSITOL 3-KINASE; BLOTTING, WESTERN; GENE EXPRESSION REGULATION, NEOPLASTIC; GLIOMA; HUMANS; MASSACHUSETTS; NEOPLASM STAGING; PREDICTIVE VALUE OF TESTS; PROSPECTIVE STUDIES; PROTEIN-SERINE-THREONINE KINASES; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS C-AKT; RIBOSOMAL PROTEIN S6 KINASES; SURVIVAL ANALYSIS; TUMOR MARKERS, BIOLOGICAL;

EID: 3042823868     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2004.07.193     Document Type: Article

References (46)

1. Walker MD, Alexander E, Hunt WE: Evaluation of BCNU and/or radiotherapy in the treatment of anaplastic gliomas. J Neurosurg 49:333-343, 1978
2. Walker MD, Green SB, Byar DP: Randomized comparisons of radiotherapy and nitrosureas for the treatment of malignant gliomas after surgery. N Engl J Med 303:1323-1329, 1980
3. Davis FG, McCarthy BJ, Freels S, et al: The conditional probability of survival of patients with primary brain tumors: Surveillance, epidemiology, and end results (SEER) data. Cancer 85:485-491, 1999
4. Cairncross JG, Ueki K, Zlatescu MC, et al: Specific genetic predictors of chemotherapeutic response and survival in patients with anaplastic oligodendrogliomas. J Natl Cancer Inst 90:1473-1479, 1998
5. Smith JS, Perry A, Borell TJ, et al: Alteration of 1p and 19q as predictors of survival in oligodendrogliomas. J Clin Oncol 18:636-645, 2000
6. Chakravarti A, Delaney MA, Noll E, et al: Prognostic and pathologic significance of quantitative protein expression profiling in human gliomas. Clin Cancer Res 7:2387-2395, 2001
7. Maher EA, Furnari FB, Bachoo RM, et al: Malignant glioma: Genetics and biology of a grave matter. Genes Dev 15:1311-1333, 2001
8. Chakravarti A, Loeffler JS, Dyson NJ: Insulin-like growth factor receptor I mediates resistance to anti-epidermal growth factor receptor therapy in primary human glioblastoma cells through continued activation of physphoinositide 3-kinase signaling. Cancer Res 62:200-207, 2002
9. Chakravarti A, Chakladar A, Delaney MA, et al: The epidermal growth factor receptor pathway mediates resistance to sequential administration of radiation and chemotherapy in primary human glioblastoma cells in a ras-dependent manner. Cancer Res 62:4307-4315, 2002
10. Barker FG, Simmons ML, Chang SM, et al: EGFR overexpression and radiation response in glioblastoma multiforme. Int J Radiat Oncol Biol Phys 51:410-418, 2001
11. Lammering G, Hewit TH, Hawkins WT, et al: Epidermal growth factor receptor as a genetic therapy target for carcinoma cell radiosensitization. J Natl Cancer Inst 93:921-929, 2001
12. Lammerling G, Valerie K, Lin P-S, et al: Radiosensitization of malignant glioma cells through overexpression of dominant-negative epidermal growth factor receptor. Clin Cancer Res 7:682-690, 2001
13. Lammering G, Lin P-S, Contessa JN, et al: Adenovirus-mediated overexpression of dominant negative epidermal growth factor receptor-CD533 as a gene therapeutic approach radiosensitizes human carcinoma and malignant glioma cells. Int J Radiat Oncol Biol Phys 51:775-784, 2001
14. Etienne M-C, Formento J-L, Lebrun-Frenay C, et al: Epidermal growth factor receptor and labeling index are independent prognostic factors in glial tumor outcome. Clin Cancer Res 4:2383-2390, 1998
15. Hackel PO, Zwick E, Prenzel N, et al: Epidermal growth factor receptors: Critical mediators of multiple receptor pathways. Curr Opin Cell Biol 11:184-189, 1999
16. Levitzki A: Protein tyrosine kinase inhibitors as novel therapeutic agents. Pharmacol Ther 82:231-239, 1999
17. Moscatello DK, Holgado-Madruga M, Emlet DR, et al: Constitutive activation of phosphatidylinositol 3-kinase by a naturally occurring mutant epidermal growth factor receptor. J Biol Chem 273:200-206, 1998
18. Nunez G, del Peso L: Linking extracellular survival signals and the apoptotic machinery. Curr Opin Neurobiol 8:613-618, 1998
19. Nelson JM, Fry DW: Akt, MARK (Erk 1,2) and p38 act in concert to promote apoptosis in response to ErbB receptor family inhibition. J Biol Chem 276:14842-14847, 2001
20. Salomon DS, Brandt R, Ciardielllo F, et al: Epidermal growth factor-related peptides and their receptors in human malignancies. Crit Rev Oncol Hematol 19:183-232, 1995
21. Schlegel J, Piontek G, Budde B, et al: The Akt/protein kinase B-dependent anti-apoptotic pathway and the mitogen-activated protein kinase cascade are alternatively activated in human glioblastoma multiforme. Cancer Lett 158: 103-108, 2000
22. Schenk PW, Snaar-Jagalska BE: Signal perception and transduction: The role of protein kinases. Biochim Biophys Acta 1449:1-24, 1999
23. Sweeney C, Fambrough D, Huard C, et al: Growth factor-specific signaling pathway stimulation and gene expression mediated by ErbB receptors. J Biol Chem 276:22685-22698, 2001
24. Contessa JN, Hampton JL, Lammering G, et al: Ionizing radiation activates Erb-B receptor dependent Akt and p70 S6 kinase signaling in carcinoma cells. Oncogene 21:4032-4041, 2002
25. Datta SR, Brunet A, Greenberg ME: Cellular survival: A play in three Akts. Genes Dev 13:2905-2927, 1999
26. Datta K, Bellacosa A, Chan TO, et al: Akt is a Direct Target of the Phosphatidylinositol 3-Kinase. J Biol Chem 271:30835-30839, 1996
27. Downward J: Mechanisms and consequences of activation of protein kinase B/Akt. Curr Opin Cell Biol 10:262-267, 1998
28. Franke TF, Kaplan DR, Cantley LC, et al: Direct regulation of the Akt proto-oncogene product by phosphatidylinositol-3,4-biphosphonate. Science 275:665-668, 1997
29. Harada H, Andersen J, Mann M, et al: P70S6 kinase signals cell survival as well as cell growth, inactivating the pro-apoptotic molecule BAD. Proc Natl Acad Sci U S A 98:9666-9670, 2001
30. Kuruvilla FG, Schreiber SL: The PIK-related kinases intercept conventional signaling pathways. Chem Biol 6:R129-R136, 1999
31. Stein RC, Waterfield MD: PI3-kinase inhibition: A target for drug development? Mol Med Today 6:347-357, 2000
32. Testa JR, Bellacosa A: AKT plays a central role in tumorigenesis. Proc Natl Acad Sci U S A 98:10983-10986, 2001
33. Xiao G-H, Jeffers M, Bellacosa A, et al: Anti-apoptotic signaling by hepatocyte growth factor/Met via the phosphatidylinositol 3-kinase/Akt and mitogen-activated protein kinase pathways. Proc Natl Acad Sci U S A 98:247-252, 2001
34. Zundel W, Giaccia A: Inhibition of the antiapoptotic pathway PI3K/Akt/bad pathway by stress. Genes Dev 12:1941-1946, 1998
35. Hall EJ: Radiobiology for the Radiologist (5th ed). Philadelphia, Lippincott Williams & Wilkins, 2000
36. Gottlob K, Majewski N, Kennedy S, et al: Inhibition of early apoptotic events by Akt/PKB is dependent on the first committed step of glycolysis and mitochondrial hexokinase. Genes Dev 15:1406-1418, 2001
37. Hidalgo M, Rowinsky EK: The rapamycin-sensitive signal transduction pathway as a target for cancer therapy. Oncogens 19:6680-6686, 2000
38. Kulik G, Weber MJ: Akt-dependent and -independent survival signaling pathways utilized by insulin-like growth factor-1. Mol Cell Biol 18: 6711-6718, 1998
39. Kulik G, Klippel A, Weber MJ: Antiapoptotic signaling by the insulin-like growth factor-1 receptor, phosphatidylinositol 3-kinase, and Akt. Mol Cell Biol 17:1595-1606, 1997
40. Plas DR, Talapatra S, Edinger AL, et al: Akt and bcl-xl promote growth-factor-independent survival through distinct effects on mitochondrial physiology. J Biol Chem 276:12041-12048, 2001
41. Nutt CL, Mani DR, Betensky RA, et al: Gene expression-based classification of malignant gliomas correlates better with survival than histological classification. Cancer Res 63:1602-1607, 2003
42. Choe G, Horvath S, Cloughesy T, et al: Analysis of the phosphatidylinositol 3-kinase signaling pathway in glioblastoma patients in vivo. Cancer Res 63:2742-2746, 2003
43. Brunet A, Datta SR, Greenberg ME: Transactivation-dependent and -independent control of neuronal survival by the PI3K-Akt signaling pathway. Curr Opin Neurobiol 11:297-305, 2001
44. Dudek H, Datta SR, Franke TF, et al: Regulation of neuronal survival by the serine-threonine protein kinase Akt. Science 275:661-665, 1997
45. Yamaguchi A, Tamatani M, Matsuzaki H, et al: Akt activation protects hippocampal neurons from apoptosis by inhibiting transcriptional activity of p53. J Biol Chem 276:5256-5264, 2000
46. Peery TS, Reardon A, Quinn J, et al: Phase II trial of ZD1839 for patients with first relapse glioblastoma. Proc Am Soc Clin Oncol 22:396, 2003 (abstr 396)